Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.

BMC Cancer · 2021 · PMC8244131 · PMID 34193107

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The NMA also showed a trend for longer OS in CAP+UTI-treated patients over ERI-treated patients, but this difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.